THE CURE TO CANCER IS ON THE WAY$$$$$$$$$$Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
MONTREAL, QC, Oct 14, 2014 (Marketwired via COMTEX) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.
"We are pleased to announce that we have selected Renmark to reinforce Sunshine Biopharma's profile in the financial community and enhance the visibility of our project portfolio. We choose Renmark because its standards and methodologies fit best with the message we wish to communicate to the investing public," noted Dr. Steve N. Slilaty, Sunshine's Chief Executive Officer.
Renmark Financial Communications does not have any interest, directly or indirectly, in Sunshine Biopharma Inc. or its securities, or any right or intent to acquire such an interest.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
